Competing interests
Zambon, Cancer
ONCOLOGY, OVARIAN CANCER, CANCER
DC reports grants from MedImmune/ AstraZeneca, Clovis, Eli Lilly, 4SC, Bayer, Celgene, NIHR EME, Leap, Roche and ownership interest and advisory role to OVIBIO. VK reports honoraria for speakers’ bureaus, personal fees and non-financial support from Accuray, Astellas, Bayer, Boston Scientific, and Janssen. DW reports sponsorship from Roche, AstraZeneca, Novartis, Pfizer for ad boards and travel fees from Roche. AW reports consulting fees from GlaxoSmithKline, Clovis, MSD and conference attendance from GlaxoSmithKline. VK reports honorarium from Servier, Roche, Amgen and Clovis Oncology pharmaceutical companies for presentation, educational meeting support, and article write-up. AG-M is a co-investigator on studies exploring novel biomarkers in ovarian cancer, funded by Micronoma and iLoF, with the research funding awarded to UCL. CP reports personal fees from Acticor Biotech, Amgen, Bayer, Eli Lilly, Tremeau, and Zambon; institutional grants from AIFA (Italian Medicines Agency), Bayer, Cancer Research UK, and European Commission; he chairs the Scientific Advisory Board of the International Aspirin Foundation. BR reports speaker fees from Swedish Orphan Biovitrum AB, a grant for an investigator-initiated trial from Bayer AG and consulting fees from Aboca. RL reports grant funding for the Add-Aspirin trial and the AsCaP collaboration, and honorarium from the Aspirin Foundation supported by Bayer. The remaining authors declare no competing interests.